what this node claims
AlphaFold metrics / SIRT1
Model-quality receipt for the fold. It is not biological validation.
vertical proof spine
evidence / risk instrument
50%
low debt pressure
24%
65%structureusable
pLDDT 65.02
78%evidenceusable
grade B
0%gatesdebt
0/5 gates
100%riskstrong
0 hard flags
22%exportdebt
no export
33%lineagedebt
incomplete spine
proof completeness
33% missing target, candidate, finding, export- 01 target
- 02 fold
- 03 alphafold metric
- 04 candidate
- 05 finding
- 06 export
Metrics and receipt inputs
- confidence band
- low
- confidence pct
- 65.02
- coverage context
- missing or not linked
- interpretation
- weak structural context; downstream claims should be conservative
- pae context
- missing or not linked
- plddt avg
- 65.02
- sequence length
- 0
AlphaFold metrics visual
Low-confidence regions present
747 residues / min 24.66 / max 98.88 / source alphafold db
Very high
36.9%
276 residues / >=90
Confident
13.0%
97 residues / 70-89
Low
3.5%
26 residues / 50-69
Very low
46.6%
348 residues / <50
weak structural context; downstream claims should be conservative
Near-complete coverage / observed 747 of 747 residues.
- residues 1-148 / mean 37.74
- residues 517-630 / mean 36.16
- residues 660-747 / mean 37.45
- residues 155-177 / mean 48.56
proof debt register
24%
Visible limits, not hidden cleanup.
Peptide RX keeps unresolved proof debt attached to the public receipt. Some debts should be resolved; redaction and research-use boundaries should stay visible.